

# Psychopharmacology

CONTENTS OF VOLUME 131 · 1997

## For North and South America

### Clinical psychopharmacology

*Field editors* D.E. Casey, Portland  
W. Potter, Indianapolis

*Advisory editors* B. Cohen, Belmont  
R. Poland, Torrance

## For the rest of the world

J. Gerlach, Roskilde  
P.J. Cowen, Oxford  
  
P. Bech, Hillerød  
W.F. Gattaz, São Paulo  
O. Lingjaerde, Oslo  
E.S. Paykel, Cambridge

### Human cognitive psychopharmacology

*Field editors* H. de Wit, Chicago

D.M. Warburton, Reading

*Advisory editors* E. Gamzu, Cambridge  
T. Roehrs, Detroit  
B.J. Spring, North Chicago  
H. Weingartner, Washington DC

I. Hindmarch, Guildford  
B.J. Sahakian, Cambridge  
K. Siegfried, Frankfurt

### Alcohol and substance abuse in humans

*Field editors* H. de Wit, Chicago

D.M. Warburton, Reading

*Advisory editors* G. Bigelow, Baltimore  
S.S. O'Malley, New Haven  
K.A. Perkins, Pittsburgh

I. Hindmarch, Guildford  
B.J. Sahakian, Cambridge  
K. Siegfried, Frankfurt

### Biochemical neuropharmacology, drug metabolism and pharmacokinetics

*Field editors* D.R. Sibley, Bethesda

J. Leysen, Beerse

*Advisory editors* I. Creese, Newark  
I. Kopin, Bethesda  
J.M. Perel, Pittsburgh

J. Heykants, Beerse  
J. Hyttel, Copenhagen-Valby  
C.A. Marsden, Nottingham  
M.B.H. Youdim, Haifa

### Behavioral pharmacology in laboratory animals

*Field editors* K.A. Miczek, Medford

T.W. Robbins, Cambridge

*Advisory editors* R.L. Balster, Richmond  
J.E. Barrett, Princeton  
J. Bergman, Southborough  
K.A. Grant, Winston-Salem  
S.G. Holtzman, Atlanta  
H. Kalant, Toronto

A.R. Cools, Nijmegen  
B.J. Everitt, Cambridge  
A.J. Goudie, Liverpool  
W. Koek, Castres  
I.P. Stolerman, London  
M.-H. Thiebot, Paris

### Preclinical psychopharmacology

*Field editors* M.A. Geyer, La Jolla

A.R. Green, Loughborough

*Advisory editors* H.C. Fibiger, Vancouver, BC  
S.D. Glick, Albany  
G.F. Koob, San Diego  
S.B. Sparber, Minneapolis  
R.A. Wise, Montreal

G. Di Chiara, Cagliari  
D.J. Heal, Nottingham  
P. Jenner, London  
H.J. Little, Durham  
J.L. Waddington, Dublin 2

# Psychopharmacology

This journal was founded as **Psychopharmacologia** in 1959 and was renamed **Psychopharmacology** beginning with Vol. 46 (1976).

The journal has been edited by the following Managing Editors:

Vol. 1 (1959), E. Rothlin and A. Wikler; Vol. 2 (1961), E. Rothlin and H. Ishell; Vol. 3 (1962), E. Rothlin and A. Wikler; Vol. 4 (1963)–Vol. 7 (1965), J.O. Cole and E. Rothlin; Vol. 8 (1965)–Vol. 16 (1969), J.O. Cole, E. Jacobsen, M.E. Jarvik, M. Shepherd; Vol. 17 (1970), J.O. Cole, E. Jacobsen, C. Kornetzky, M. Shepherd; Vol. 18 (1970)–Vol. 27 (1972), J.O. Cole, M. Hamilton, E. Jacobsen, C. Kornetzky; Vol. 28 (1973)–Vol. 35 (1974), J.O. Cole, M. Hamilton, E. Jacobsen, C. Kornetzky, R.W. Russell; Vol. 36 (1974)–Vol. 69 (1980), H. Barry III, J.O. Cole, M. Hamilton, E. Jacobsen, R.W. Russell; Vol. 70 (1980)–Vol. 77 (1982), H. Barry III, J.O. Cole, M. Hamilton, T.W. Robbins, R.W. Russell.

Starting with Vol. 80 (1983) the Editors have been: H. Barry III, T.W. Robbins (Coordinating Editors), J.O. Cole, J. Gerlach, M. Hamilton, J. Leysen, F. Sulser. As of Vol. 85 (1985): H. Barry III, D.E. Casey, J.O. Cole, J. Gerlach, S.D. Glick, A.R. Green, M. Hamilton, J. Leysen, T.W. Robbins, F. Sulser. As of Vol. 92 (1987): H. Barry III, D.E. Casey, J. Gerlach, S.D. Glick, A.R. Green, J. Leysen, T.W. Robbins, B.J. Spring, F. Sulser, D.M. Warburton. As of Vol. 98 (1989): H. Barry III, D.E. Casey, J. Gerlach, S.D. Glick, A.R. Green, J. Leysen, T.W. Robbins, D.R. Sibley, B.J. Spring, D.M. Warburton. As of Vol. 106 (1992): D.E. Casey, J. Gerlach, M.A. Geyer, A.R. Green, J. Leysen, K.A. Miczek, T.W. Robbins, D.R. Sibley, B.J. Spring, D.M. Warburton. As of Vol. 109 (1992): D.E. Casey, J. Gerlach, M.A. Geyer, A.R. Green, J. Leysen, K.A. Miczek, T.W. Robbins, D.R. Sibley, B.J. Spring, D.M. Warburton, H. de Wit. As of Vol. 117 (1995): D.E. Casey, J. Gerlach, M.A. Geyer, A.R. Green, J. Leysen, K.A. Miczek, T.W. Robbins, D.R. Sibley, D.M. Warburton, H. de Wit. As of Vol. 129 (1997): D.E. Casey, P.J. Cowen, J. Gerlach, M.A. Geyer, A.R. Green, J. Leysen, K.A. Miczek, W. Potter, T.W. Robbins, D.R. Sibley, D.M. Warburton, H. de Wit.

## Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institution where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made.

The publisher makes no warranty, express or implied, with respect to the material contained herein.

*Special regulations for photocopies in the USA:* Photocopies may be made for personal or in-house use beyond the limitations stipulated under Section 107 or 108 of U.S. Copyright Law, provided a fee is paid. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0033-3158, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

The Canada Institute for Scientific and Technical Information (CISTI) provides a comprehensive, world-wide document delivery service for all Springer-Verlag journals. For more information, or to place an order for a copyright-cleared Springer-Verlag document, please contact Client Assistant, Document Delivery, Canada Institute for Scientific and Technical Information, Ottawa K1A 0S2, Canada, Tel. (613) 993-9251, FAX (613) 952-8243, e-mail: cisti.docdel@nrc.ca

## ADONIS Identification System

The journal Psychopharmacology appears twice a month. It is published by Springer-Verlag Berlin, Heidelberger Platz 3, D-14197 Berlin. This journal is included in the ADONIS service, whereby copies of individual articles can be printed out from compact discs (CD-ROM) on demand. An explanatory leaflet giving further details of the scheme is available from the publishers on request.

## Journals Preview Service

This journal is included in the Springer Journals Preview Service, i.e. the tables of contents and BiblioAbstracts are available via Internet before the new issue reaches the subscribers. Tables of contents are free of charge. BiblioAbstracts are available for a small annual fee. Details can be obtained by sending an e-mail message containing the line help to svjps@springer.de

## Printers

Universitätsdruckerei H. Stürtz AG,  
Würzburg, Germany

## Publisher

© Springer-Verlag Berlin Heidelberg 1997  
Springer-Verlag GmbH & Co. KG Berlin,  
Germany

Printed in Germany



Springer

## Contents of Volume 131 · 1997

- Abe Y → Kudo S  
Akashi K → Morioka C  
Andreassen OA, MacEwan T, Gulbrandsen A-K, McCreadie RG, Steen VM: Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenia patients 174  
Andrée B, Halldin C, Vrijmoed-de Vries M, Farde L: Central 5-HT<sub>2A</sub> and D<sub>2</sub> dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men 339  
Andrews MM → Roberts DCS  
Anton RF, Kranzler HR, McEvoy JP, Moak DH, Bianca R: A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal 123  
Apfelbaum JL → Conley KM  
ARCS Study Group → Jeste DV
- Balcells-Olivero M, Vezina P: Effects of naltrexone on amphetamine-induced locomotion and rearing: acute and repeated injections 230  
Bannerman A → Elliott R  
Baumann MH → Shoaib M  
Bell SM, Stewart RB, Thompson SC, Meisch RA: Food-deprivation increases cocaine-induced conditioned place preference and locomotor activity in rats 1  
Bianca R → Anton RF  
Biggio G → Motzo C  
Blanco-Centurión C → Salín-Pascual RJ  
Bonhomme N → Lucas G  
Boone KB → Poland RE  
Borg S → Saxon L  
Bourin M → Volke V  
Brammer GL → Poland RE  
Brecher M → Jeste DV  
Breese GR → Moy SS  
Byrd LD → Howell LL
- Carter DB → Tang AH  
Casal L → Krystal JH  
Charney DS → Krystal JH  
Clyde C → Jeste DV  
Compaan JC → Groenink L  
Conley KM, Toledano AY, Apfelbaum JL, Zacyn JP: Modulating effects of a cold water stimulus on opioid effects in volunteers 313  
Conway SC → Goodwin GM  
Cooney N → Krystal JH  
Cooper SJ → Higgs S  
Costall B → Smith JK  
Criswell HE → Moy SS  
Czoty PW → Howell LL
- Danion JM → Peretti CS  
Davis M → Krystal JH  
Dazzi L → Motzo C  
De Deurwaerdère P → Lucas G  
De Vries TJ → Vanderschuren LJMJ  
Deuschle M, Härtter S, Hiemke C, Standhardt H, Heuser I: Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients 19
- Dewe SL → Ding Y-S  
Ding Y-S, Fowler JS, Volkow ND, Dewey SL, Wang G-J, Logan J, Gatley SJ, Pappas N: Chiral drugs: comparison of the pharmacokinetics of [<sup>14</sup>C]*d*-threo and *I*-threo-methylphenidate in the human and baboon brain 71  
D'Amico D → Perkins KA  
Drucker-Colin R → Salín-Pascual RJ
- Ebmeier KP → Goodwin GM  
Ellinwood EHJr → Hege SG  
Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW: Effects of methylphenidate on spatial working memory and planning in healthy young adults 196  
Erp AMM van, Miczek KA: Increased aggression after ethanol self-administration in male resident rats 287  
Ettenberg A → McFarland K
- Farde L → Andrée B  
Field MJ → Rupniak NMJ  
Fowler JS → Ding Y-S  
France CP → Gerak LR  
Franklin SR → Tang AH  
Furukawa M → Kudo S  
Furukawa T → Morioka C
- García-Ferreiro R → Salín-Pascual RJ  
Gatley SJ → Ding Y-S  
Gerak LR, France CP: Repeated administration of flumazenil does not alter its potency in modifying schedule-controlled behavior in chlordiazepoxide-treated rhesus monkeys 64  
Glabus MF → Goodwin GM  
Goldberg SR → Shoaib M  
Goldman NH → Rush CR  
Goodwin GM, Conway SC, Peyro-Saint-Paul H, Glabus MF, O'Carroll RE, Ebmeier KP: Executive function and uptake of <sup>99m</sup>Tc-exametazime shown by single photon emission tomography after oral idazoxan in probable Alzheimer-type dementia 371  
Graham SM → Hege SG  
Grangé D → Peretti CS  
Griebel G, Perrault G, Sanger DJ: Behavioural profiles of the reversible monoamine-oxidase-A inhibitors belfloxtatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs 180  
Grillon C → Krystal JH  
Grob CS → Poland RE  
Groenink L, Van der Gugten J, Compaan JC, Maes RAA, Olivier B: Flesinoxan pretreatment differentially affects corticosterone, prolactin and behavioural responses to a flesinoxan challenge 93  
Gulbrandsen A-K → Andreassen OA
- Halldin C → Andrée B  
Härtter S → Deuschle M  
Hayes CA → Rush CR
- Hege SG, Ellinwood EHJr, Wilson WH, Hellingers CAM, Graham SM: Psychomotor effects of the anxiolytic abecarnil: a comparison with lorazepam 101  
Hellingers CAM → Hege SG  
Hernández LL, Watson KL: Opioid modulation of attention-related responses: delta-receptors modulate habituation and conditioned bradycardia 140  
Heuser I → Deuschle M  
Hiemke C → Deuschle M  
Higashima M, Kinoshita H, Yamaguchi N, Koshino Y: Differences in enhancing effects of zolpidem and benzodiazepine drugs on recurrent inhibition in rat hippocampal slices 394  
Higgs S, Cooper SJ: Midazolam-induced rapid changes in licking behaviour: evidence for involvement of endogenous opioid peptides 278  
Hiltunen AJ → Saxon L  
Hinchliffe RM → Woodruff-Pak DS  
Hitchcock PK, Phillips GD: Amygdala and hippocampus control dissociable aspects of drug-associated conditioned rewards 187  
Hjemdahl P → Saxon L  
Houle S → Kapur S  
Howell LL, Czoty PW, Byrd LD: Pharmacological interactions between serotonin and dopamine on behavior in the squirrel monkey 40
- Jackson DM → Johansson C  
Jacobsen EJ → Tang AH  
Jeste DV, Klausner M, Brecher M, Clyde C, Jones R, ARCS Study Group: A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial 239  
Johansson C, Jackson DM, Svensson L: Nitric oxide synthase inhibition blocks phenylcyclidine-induced behavioural effects on pre-pulse inhibition and locomotor activity in the rat 167  
Johnson CA → Rush CR  
Jones C → Kapur S  
Jones R → Jeste DV
- Kaneko T, Thompson RF: Disruption of trace conditioning of the nictitating membrane response in rabbits by central cholinergic blockade 161  
Kapur S, Zipursky R, Roy P, Jones C, Remington G, Reed K, Houle S: The relationship between D<sub>2</sub> receptor occupancy and plasma levels on low dose oral haloperidol: a PET study 148  
Kauffmann-Muller F → Peretti CS  
Kempainen S → Riekkinen M  
Kikuchi T, Uwahodo Y, Tottori K, Nakai M, Morita S: The attenuating effect of carteolol hydrochloride, a β-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats 108  
Kinoshita H → Higashima M  
Klausner M → Jeste DV

- Kleven MS, Koek W: Discriminative stimulus properties of cocaine: enhancement by  $\beta$ -adrenergic receptor antagonists 307  
 Knapp DJ → Moy SS  
 Koek W → Kleven MS  
 Koks S → Volke V  
 Kondo H → Morioka C  
 Koshino Y → Higashima M  
 Kranzler HR → Anton RF  
 Krystal JH, Webb E, Grillon C, Cooney N, Casal L, Morgan III CA, Southwick SM, Davis M, Charney DS: Evidence of acoustic startle hyperreflexia in recently detoxified early onset male alcoholics: modulation by yohimbine and *m*-Chlorophenylpiperazine (mCPP) 207  
 Kudo S, Umehara K, Abe Y, Furukawa M, Odomi M: Intracerebral penetration of carbofyll hydrochloride in rats 388  
 Le Moal M → Lucas G  
 Lee MD, Simansky KJ: CP-94,253: a selective serotonin<sub>1B</sub> (5-HT<sub>1B</sub>) agonist that promotes satiety 264  
 Livermore CL → Nation JR  
 Logan J → Ding Y-S  
 Lucas G, Bonhomme N, De Duerwaerdère P, Le Moal M, Spampinato U: 8-OH-DPAT, a 5-HT<sub>1A</sub> agonist and ritanserin, a 5-HT<sub>2A/C</sub> antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release 57  
 Lutchmansingh P → Poland RE  
 MacEwan T → Andreassen OA  
 Madakasira S → Rush CR  
 Maes RAA → Groenink L  
 Makinaga G → Morioka C  
 Maldonado R → Valverde O  
 Männistö PT → Volke V  
 Marsden CA → Mongeau R  
 Matsumura K → Morioka C  
 Matthews K → Elliott R  
 McCracken JT → Poland RE  
 McCreadie RG → Andreassen OA  
 McEvoy JP → Anton RF  
 McFarland K, Ettenberg A: Reinstatement of drug-seeking behavior produced by heroin-predictive environmental stimuli 86  
 Meisch RA → Bell SM  
 Miczek KA → Erp AMM van  
 Miller DK → Nation JR  
 Misawa M → Suzuki T  
 Moak DH → Anton RF  
 Mongeau R, Marsden CA: Effect of imipramine treatments on the 5-HT<sub>1A</sub>-receptor-mediated inhibition of panic-like behaviours in rats 321  
 Morgan III CA → Krystal JH  
 Mori T → Suzuki T  
 Morioka C, Kondo H, Akashi K, Matsumura K, Ochi N, Makinaga G, Furukawa T: The continuous and simultaneous blood flow velocity measurement of four cerebral vessels and a peripheral vessel during cigarette smoking 220  
 Morita S → Kikuchi T  
 Moro-López ML → Salin-Pascual RJ  
 Motzo C, Porceddu ML, Dazzi L, Sanna A, Serra M, Biggio G: Enhancement by flumazenil of dopamine release in the nucleus accumbens of rats repeatedly exposed to diazepam or imidazepinil 34  
 Moy SS, Knapp DJ, Criswell HE, Breese GR: Flumazenil blockade of anxiety following ethanol withdrawal in rats 354  
 Mulder AH → Vanderschuren LJM  
 Nakai M → Kikuchi T  
 Nation JR, Miller DK, Livermore CL: Chronic exposure to cadmium attenuates behavioral sensitization to morphine 248  
 Needham LM → Tang AH  
 Neill JC → Smith JK  
 Nestby P → Vanderschuren LJM  
 Ochi N → Morioka C  
 Odomi M → Kudo S  
 Olivier B → Groenink L  
 Onodera K → Suzuki T  
 O'Carroll RE → Goodwin GM  
 Pappas N → Ding Y-S  
 Patat A → Peretti CS  
 Pazzaglia PJ → Rush CR  
 Pechnick RN → Poland RE  
 Peretti CS, Danion JM, Kauffmann-Muller F, Grangé D, Patat A, Rosenzweig P: Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers 329  
 Perkins KA, Sanders M, D'Amico D, Wilson A: Nicotine discrimination and self-administration in humans as a function of smoking status 361  
 Perrault G → Griebel G  
 Peyro-Saint-Paul H → Goodwin GM  
 Phillips GD → Hitchcock PK  
 Poland RE, Lutchmansingh P, McCracken JT, Zhao J-P, Brammer GL, Grob CS, Boone KB, Pechnick RN: Abnormal ACTH and prolactin responses to fenfluramine in rats exposed to single and multiple doses of MDMA 411  
 Porceddu ML → Motzo C  
 Reed K → Kapur S  
 Remington G → Kapur S  
 Riekkinen M, Kempainen S, Riekkinen P Jr: Effects of stimulation of alpha<sub>1</sub>-adrenergic and NMDA/glycine-B receptors on learning defects in aged rats 49  
 Riekkinen P Jr → Riekkinen M  
 Rimmer J → Elliott R  
 Robbins TW → Elliott R  
 Roberts DCS, Andrews MM: Baclofen suppression of cocaine self-administration: demonstration using a discrete trials procedure 271  
 Roques BP → Valverde O  
 Rosenzweig P → Peretti CS  
 Rothman RB → Shoaib M  
 Roy P → Kapur S  
 Rupniak NMJ, Tye SJ, Field MJ: Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys 406  
 Rush CR, Madakasira S, Hayes CA, Johnson CA, Goldman NH, Pazzaglia PJ: Trazodone and triazolam: acute subject-rated and performance-impairing effects in healthy volunteers 9  
 Sahakian BJ → Elliott R  
 Salin-Pascual RJ, García-Ferreiro R, Moro-López ML, Blanco-Centurión C, Drucker-Colín R: Repeated REM sleep deprivation after chronic haloperidol administration in the rat 216  
 Sanders M → Perkins KA  
 Sanger DJ → Griebel G  
 Sanna A → Motzo C  
 Saxon L, Hjemdahl P, Hiltunen AJ, Borg S: Effects of flumazenil in the treatment of benzodiazepine withdrawal – a double-blind pilot study 153  
 Schindler CW → Shoaib M  
 Schoffelmeer ANM → Vanderschuren LJM  
 Serra M → Motzo C  
 Sethy VH → Tang AH  
 Shoaib M, Baumann MH, Rothman RB, Goldberg SR, Schindler CW: Behavioural and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats 296  
 Simansky KJ → Lee MD  
 Smadja C → Valverde O  
 Smith JK, Neill JC, Costall B: Post-weaning housing conditions influence the behavioural effects of cocaine and *d*-amphetamine 23  
 Soosaar A → Volke V  
 Southwick SM → Krystal JH  
 Spampinato U → Lucas G  
 Standhardt H → Deuschle M  
 Steen VM → Andreassen OA  
 Stewart RB → Bell SM  
 Suzuki T, Mori T, Tsuji M, Misawa M, Onodera K: Interactions between H<sub>1</sub>-antagonists and opioids: a drug discrimination study 346  
 Svensson L → Johansson C  
 Tang AH, Franklin SR, Carter DB, Sethy VH, Needham LM, Jacobsen EJ, Von Voigtlander PF: Anxiolytic-like effects of PNU-101017, a partial agonist at the benzodiazepine receptor 255  
 Thompson RF → Kaneko T  
 Thompson SC → Bell SM  
 Tjon GHK → Vanderschuren LJM  
 Toledano AY → Conley KM  
 Tottori K → Kikuchi T  
 Tsuji M → Suzuki T  
 Tye SJ → Rupniak NMJ  
 Umehara K → Kudo S  
 Uhahodo Y → Kikuchi T  
 Valverde O, Smadja C, Roques BP, Maldonado R: The attenuation of morphine-conditioned place preference following chronic mild stress is reversed by a CCK<sub>B</sub> receptor antagonist 79  
 Van der Gugten J → Groenink L  
 Vanderschuren LJM, Tjon GHK, Nestby P,

Mulder AH, Schoffelmeer ANM, De Vries TJ: Morphine-induced long-term sensitization to the locomotor effects of morphine and amphetamine depends on the temporal pattern of the pretreatment regimen 115  
 Vasar E → Volke V  
 Vezina P → Balcells-Olivero M  
 Volke V, Soosaar A, Köks S, Bourin M, Männistö PT, Vasar E: 7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety 399  
 Volkow ND → Ding Y-S  
 Von Voigtlander PF → Tang AH

Vrijmoed-de Vries M → Andrée B  
 Wang G-J → Ding Y-S  
 Watson KL → Hernández LL  
 Webb E → Krystal JH  
 Wilson A → Perkins KA  
 Wilson WH → Hege SG  
 Woodruff-Pak DS, Hinchliffe RM: Mecamylamine- or scopolamine-induced learning impairment: ameliorated by nefiracetam 130  
 Yamaguchi N → Higashima M  
 Yamamoto J: Cortical and hippocampal EEG

power spectra in animal models of schizophrenia produced with methamphetamine, cocaine, and phencyclidine 379

Zacny JP → Conley KM  
 Zhao J-P → Poland RE  
 Zipursky R → Kapur S

Indexed in *Current Contents*,  
*Psychological Abstracts*,  
*Psyc INFO*, *Index Medicus* and in *EMBASE*

## Subject index of Volume 131 · 1997

- Abecarnil 101, 123
- Acetylcholine 406
- ACTH 411
- Acute and chronic treatments 180
- $\beta$ -Adrenergic receptors 307
- Adrenoceptor 371
- Aged rat 49
- Aggression 287
- Aging 130
- Akathisia 108, 174
- Alcohol 287
- Alcohol withdrawal 123
- Alpha<sub>1</sub>-adrenoceptor 49
- Alzheimer's disease 130, 406
- Alzheimer-type dementia 371
- Amisulpride 329
- Amphetamine 115, 167, 230
- d-Amphetamine 23, 187
- Analgesia 313
- Animal model 321, 379
- Antidepressants 9
- Antipsychotic 239
- Anti-psychotic drugs 174
- Antipsychotic drugs 339
- Anxiety 93, 180, 321, 354, 399
- Anxiolytic 101, 255
- Apomorphine 40
- Attention 140
- Autonomic conditioning 140
- Baclofen 271
- Basolateral area of the amygdala 187
- Beflroxatone 180
- Behavior 248
- Behavioural sensitization 115
- Benzodiazepine 64, 101, 255, 394
- Benzodiazepine receptor partial agonist 34
- Benzodiazepines 9, 153, 278, 354
- Betaxolol 307
- $\beta$ -Blocker 388
- Bout structure 278
- Brain 388
- Butorphanol 313
- Cadmium 248
- $\beta$ -Carboline 101
- Carteolol hydrochloride 108, 388
- Catalepsy 57, 108
- CCK<sub>B</sub> receptor antagonist 79
- D-cycloserine 49
- Central cholinergic nervous system 161
- Cerebral blood flow 220
- Chiral drugs 71
- Chlordiazepoxide 64
- m-Chlorophenylpiperazine (mCPP) 207
- Chronic unpredictable mild stress 79
- Cigarette smoking 220
- Classical conditioning 161
- CNQX 187
- Cocaine 1, 23, 271, 307, 379
- Cognition 196, 406
- Cognition-enhancing 130
- Cognitive 329
- Cognitive enhancer 371
- Cognitive tasks 101
- Conditioned place preference 1, 79
- Conditioned reinforcement 23
- Conditioned reward 187
- Cortex 379
- Corticosterone 93
- Corticotropin-releasing factor 354
- CP-93,129 264
- CP-94,253 264
- CSF 19
- CYP2D6 genotype 174
- Defensive behaviours 180
- Defensive burying 93
- Delay procedure 161
- Delta opioid antagonist 140
- Delta opioid receptors 140
- Dependence 64
- Depression 79
- Discrete trials procedure 271
- Discrimination 361
- Dopamine 40, 57, 86, 196, 216, 296
- Dopamine D<sub>2</sub> receptor 148
- Dopamine receptors 339
- Dopamine release 34
- Dopamine transporter 71
- Dose versus dose discrimination 307
- Doxepin 19
- Doxepin metabolites 19
- Drug discrimination 296, 307, 346
- Drug interaction 346
- Drug relapse 86
- Drug self-administration 40
- Dyskinesia 239
- EEG power spectra 379
- Elevated plus maze 354
- Environmental enrichment 23
- Ethanol dependence 207
- Ethanol withdrawal 207
- Extrapyramidal side effects 108
- Extrapyramidal symptoms 239
- Eyeblink classical conditioning 130
- Feeding 264
- Fenfluramine 296, 411
- Fixed-interval schedule 40
- Flesinoxan 93
- Flight 180
- Flumazenil 64, 153
- Food-deprivation 1
- Frontal cortex 371
- GABA 271, 394
- GABA<sub>A</sub> receptor 255
- GBR 12909 40
- Glycine-B binding site 49
- H<sub>1</sub>-antagonist 346
- Haloperidol 57, 86, 148, 216, 329
- Heart rate 140
- Heroin self-administration 86
- Hippocampus 161, 379, 394
- 5-HT<sub>1A</sub> 93
- Human 313, 329
- Human brain 339
- Humans 9, 101, 153
- Hypnotic 394
- Hypnotics 9
- ICI 118,551 307
- Idazoxan 371
- Imipramine 79
- Individual differences 287
- Internal carotid artery 220
- Intracranial self-administration 187

- Learning 9, 140  
 Licking behaviour 278  
 Locomotion 230  
 Locomotor activity 1, 23, 115, 167  
 Long-term treatment 34  
 Meal size 264  
 Memory 9, 130, 329  
 Methamphetamine 379  
 3,4-Methylenedioxymethamphetamine (MDMA) 411  
 Methylphenidate 71  
 Microdialysis 57, 296  
 Microstructure of ingestion 264  
 (-)-Propranolol 307  
 Moclambemide 180  
 Morphine 79, 115, 248, 313  
 Motivation 86  
 Motor 329  
 Motor side-effects 174  
 Mouse 399  
 Muscarinic receptors 130  
 Nadolol 307  
 Naltrexone 230  
 Naltrindole 140  
 Negative symptoms 239  
 Neuroleptics 108  
 Neurotoxicity 411  
 Nicotine 361  
 Nicotinic receptors 130  
 Nicitating membrane response 161  
 Nitric oxide 167  
 Nitric oxide synthase 399  
 7-Nitroindazole 399  
 Nootropic 130  
 Noradrenaline 207  
 Nucleus accumbens 34, 187  
 8-OH-DPAT 57  
 Operant behavior 40  
 Opiate 313  
 Opiate-dopamine interactions 230  
 Opioid 313, 346  
 Opioids 230, 278  
 Oral self-administration 287  
 ORG 5222 339  
 Orienting responses 140  
 Pain 313  
 Palatability 278  
 Palliative therapy 406  
 Panic 180  
 Panic disorder 321  
 Parkinsonism 174  
 Partial agonist 255  
 Partial benzodiazepine agonists 123  
 Pavlovian (classical) conditioning 140  
 PD-134,308 79  
 Penetrability 388  
 Performance 9  
 Periaqueductal grey 321  
 Peripheral blood flow 220  
 PET 339  
 Pharmacodynamics 101  
 Phencyclidine 167, 379  
 Phentermine 296  
 Plasma 19  
 Plasma levels 148  
 Poor metabolizer 174  
 Positron emission tomography 71, 339  
 Positron Emission Tomography (PET) 148  
 Prepulse inhibition 167  
 Pretreatment regimen 115  
 Prolactin 93, 411  
 Psychomotor 313  
 Psychomotor skills 101  
 Psychomotor stimulant 196, 230  
 Psychosis 239  
 Quinpirole 40  
 Rabbit 140, 379  
 $[^{14}\text{C}]$ -Raclopride 148  
 Radial artery 220  
 Rat 1, 23, 167, 287, 388, 399  
 Rearing 230  
 Recall 9  
 Receptor occupancy 148  
 $5\text{-HT}_{1B}$  receptors 264  
 Recurrent inhibition 394  
 Reinforcement 1, 86, 361  
 REM sleep deprivation 216  
 Repeated drug administration 93  
 Reversible monoamine oxidase inhibitors 180  
 Reward 1, 23, 79  
 Rhesus monkeys 64  
 Risk assessment 180  
 Ritalin 71  
 Ritanserin 57  
 Satiety 264  
 Schedule-controlled behavior 64  
 Schizophrenia 167, 174, 379  
 Scopolamine 161  
 Second-order schedule 40  
 Self-administration 271, 361  
 Sensitisation 23  
 Sensitization 1, 230, 248  
 Serotonergic system 321  
 Serotonin 40, 57, 207, 264, 296  
 Serotonin (5-HT) 411  
 Serotonin receptors 339  
 Sex differences 361  
 Skill learning 329  
 Smoking status 361  
 Social isolation 23  
 Squirrel monkey 40  
 ST 587 49  
 Startle 207  
 Stereoselectivity 71  
 Stress 79, 354  
 Striatum 57  
 Subjective 313  
 Subjective effects 361  
 Sublingual administration 339  
 Swiss mouse 180  
 Tacrine 406  
 Tardive dyskinesia 174  
 Tertatolol 307  
 Time course 115  
 Tolerance 361  
 Trace procedure 161  
 Trazodone 9  
 Treatment 123  
 Triazolam 9  
 Tricyclic antidepressant drugs 321  
 Ultrasonics 220  
 Ventral subiculum 187  
 Vertebral artery 220  
 Water maze 49  
 Weight-reduction 1  
 Withdrawal 153  
 Withdrawal syndrome 34  
 Yohimbine 207  
 Zolpidem 394

